Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis
We conducted a retrospective analysis of 213 patients with HER2+ T1micN0 breast cancer. Patients with ≥5 foci of microinvasion received more aggressive treatment with higher rates of sentinel lymph node biopsy and adjuvant chemotherapy/HER2-targeted therapy (CT/H2TT) than patients with 1-4 foci. We did not detect significant differences in invasive disease-free survival between patients with 1-4 and ≥5 foci, or between patients with ≥5 foci who did and did not receive adjuvant CT/H2TT.
Authors
- Andrew D. Seidman (ORCID: https://orcid.org/0000-0002-5064-3966)
- Celine Yeh (ORCID: https://orcid.org/0000-0003-4663-4108)
- Rachel Han (ORCID: https://orcid.org/0000-0002-5999-3997)
- Charlie White (ORCID: https://orcid.org/0000-0003-1671-3155)
- Abha Kulkarni (ORCID: https://orcid.org/0000-0003-2365-6582)
- Edi Brogi (ORCID: https://orcid.org/0000-0003-4737-8468)
- Yuan Chen (ORCID: https://orcid.org/0000-0001-6467-4088)
- Matthew G Hanna
Institutions
- Sunnybrook Health Science Centre (CA)
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- University of Pittsburgh Medical Center (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1038/s41523-025-00759-2
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05